News
UCSF researchers found the cancer drugs letrozole and irinotecan may reverse Alzheimer's effects, reducing tau protein clumps ...
Early-onset Alzheimer's, affecting individuals under 65, presents unique challenges with memory, thinking, and daily ...
Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation ...
Johnson & Johnson (NYSE: JNJ) today announced promising new data from its Alzheimer's disease (AD) research program will be presented at the Alzheimer's Association International Conference (AAIC), ...
1d
GlobalData on MSNRoche’s Elecsys pTau181 test gains CE Mark to rule out Alzheimer’sA multi-centre, prospective trial involving 787 subjects across Australia, Europe, and the US formed the basis for the CE ...
The model reveals that more connected brain regions are more prone to damage, while isolated areas remain resilient. This approach offers a powerful framework for understanding disease progression and ...
Researchers are investigating blood-based biomarkers like pTau217 for Alzheimer’s detection, offering a less invasive ...
6d
ABP News on MSNThe Stages Of Alzheimer’s Disease — And How Families Can PrepareUnderstand the 6 stages of Alzheimer’s disease, from early signs to final care, and how families can support loved ones ...
Lexington, Massachusetts Tuesday, July 22, 2025, 18:00 Hrs [IST] ...
16h
IFLScience on MSNCOVID-19 Can Lead To Build Up Of Alzheimer’s-Linked Protein Clumps In Eyes And BrainPeople with Alzheimer’s have high levels of amyloid-β in their brains, but the team also learned that this was the case in ...
Elecsys pTau181 is the first In Vitro Diagnostic Regulation (IVDR) certified test to rule out Alzheimer’s associated amyloid ...
Li, Huang, and Sirota chose 2 cancer drugs out of the top 5 drug candidates for laboratory testing. They predicted one drug, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results